Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 18 04:00PM ET
1.44
Dollar change
-0.01
Percentage change
-0.69
%
Index- P/E1.13 EPS (ttm)1.27 Insider Own5.25% Shs Outstand37.21M Perf Week-10.56%
Market Cap53.58M Forward P/E- EPS next Y-0.29 Insider Trans0.00% Shs Float35.25M Perf Month-19.10%
Income72.20M PEG- EPS next Q0.07 Inst Own43.03% Short Float2.96% Perf Quarter-13.25%
Sales135.87M P/S0.39 EPS this Y210.43% Inst Trans-0.19% Short Ratio4.98 Perf Half Y-56.50%
Book/sh2.47 P/B0.58 EPS next Y-117.66% ROA55.36% Short Interest1.04M Perf Year12.50%
Cash/sh2.38 P/C0.61 EPS next 5Y- ROE132.23% 52W Range1.15 - 3.87 Perf YTD-35.43%
Dividend Est.- P/FCF- EPS past 5Y30.97% ROI67.81% 52W High-62.79% Beta1.59
Dividend TTM- Quick Ratio6.88 Sales past 5Y-53.56% Gross Margin98.60% 52W Low25.22% ATR (14)0.10
Dividend Ex-Date- Current Ratio7.66 EPS Y/Y TTM163.63% Oper. Margin53.91% RSI (14)25.83 Volatility6.86% 6.12%
Employees36 Debt/Eq0.16 Sales Y/Y TTM3162.94% Profit Margin53.14% Recom1.00 Target Price6.83
Option/ShortYes / Yes LT Debt/Eq0.16 EPS Q/Q94.11% Payout- Rel Volume1.60 Prev Close1.45
Sales Surprise-70.12% EPS Surprise70.15% Sales Q/Q13.10% EarningsNov 13 AMC Avg Volume209.75K Price1.44
SMA20-12.38% SMA50-20.66% SMA200-37.19% Trades Volume335,013 Change-0.69%
Date Action Analyst Rating Change Price Target Change
Jan-22-21Initiated Guggenheim Buy $25
Jan-06-21Initiated Cantor Fitzgerald Overweight $30
Jul-11-18Upgrade Needham Hold → Buy $5
Jun-27-18Initiated Maxim Group Buy $6
Oct-24-17Initiated Guggenheim Buy $6
Jul-10-17Initiated ROTH Capital Buy $8.50
May-09-17Downgrade Needham Buy → Hold
Mar-03-17Reiterated RBC Capital Mkts Outperform $15 → $11
Oct-20-16Initiated H.C. Wainwright Buy $14
Oct-07-16Upgrade WBB Securities Buy → Strong Buy $8
Jan-30-24 04:05PM
Jan-29-24 05:15PM
Jan-05-24 08:30AM
Dec-27-23 09:30AM
Nov-27-23 10:33AM
01:15PM Loading…
Nov-15-23 01:15PM
Nov-13-23 05:55PM
05:17PM
Oct-24-23 08:00AM
Oct-18-23 09:00PM
Oct-16-23 08:00AM
Oct-02-23 09:00PM
Sep-27-23 08:31PM
07:49AM
Sep-25-23 08:55AM
04:00AM Loading…
Sep-20-23 04:00AM
Sep-04-23 01:31PM
Aug-28-23 10:17PM
08:00AM
Aug-14-23 04:59PM
04:30PM
Aug-11-23 09:09AM
Jul-20-23 09:58AM
Jun-26-23 02:20PM
07:00AM
Jun-21-23 07:00AM
Jun-15-23 04:10PM
May-19-23 09:22AM
May-12-23 08:00AM
May-11-23 08:45AM
07:37AM Loading…
07:37AM
07:00AM
May-08-23 03:38PM
Apr-13-23 08:30AM
Apr-11-23 01:33PM
Mar-31-23 12:31PM
08:30AM
Mar-30-23 01:12PM
09:36AM
07:05AM
Mar-22-23 09:25AM
07:06AM
Mar-01-23 04:03PM
Jan-14-23 07:43AM
Dec-01-22 08:00AM
Nov-30-22 08:30AM
Nov-17-22 08:30AM
Nov-11-22 05:37AM
Nov-09-22 08:15AM
07:00AM
Nov-07-22 08:30AM
Nov-03-22 08:30AM
Nov-02-22 10:01AM
Nov-01-22 08:30AM
Oct-25-22 08:30AM
Oct-24-22 08:30AM
Oct-20-22 07:00AM
Oct-11-22 08:30AM
Oct-07-22 09:25AM
Sep-09-22 08:30AM
Sep-08-22 08:30AM
Sep-01-22 08:30AM
Aug-15-22 08:15AM
07:00AM
Aug-09-22 08:30AM
Aug-04-22 08:30AM
Aug-01-22 08:30AM
Jul-19-22 08:30AM
Jul-14-22 08:30AM
Jun-29-22 07:06AM
Jun-23-22 08:30AM
Jun-08-22 08:30AM
Jun-03-22 04:05PM
May-20-22 08:30AM
May-12-22 08:35AM
07:00AM
May-10-22 08:30AM
May-05-22 08:30AM
May-04-22 08:30AM
Apr-30-22 08:55AM
Apr-27-22 08:30AM
Apr-26-22 05:18PM
Apr-22-22 08:15AM
08:00AM
Apr-21-22 04:01PM
Apr-20-22 08:30AM
Apr-19-22 08:30AM
Apr-09-22 08:03AM
Apr-04-22 09:59AM
Mar-31-22 01:37PM
Mar-29-22 08:15AM
07:00AM
Mar-24-22 08:30AM
Mar-08-22 08:30AM
Mar-04-22 05:00PM
Mar-02-22 08:30AM
Feb-13-22 07:43AM
Feb-10-22 07:36AM
Feb-03-22 04:15PM
Jan-20-22 10:13AM
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.